MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
illi News/10248395

Trending...
CHICAGO ~ MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA" or the "Company"), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, recently announced that it has closed its previously announced registered direct offering for the issuance and sale of an aggregate of 2,424,243 of its shares of common stock at a purchase price of $1.65 per share. In a concurrent private placement, MAIA also issued and sold unregistered warrants to purchase up to an aggregate of 2,424,243 shares of its common stock.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to MAIA from the offering were approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by the Company. MAIA currently intends to use the net proceeds from the offering for working capital and general corporate purposes as well as to fund research and development activities.

More on illi News
The unregistered warrants have an exercise price $1.86 per share, become exercisable six months following issuance and will expire five and one-half years from the date of issuance. The shares of common stock offered in the registered direct offering (but excluding the unregistered warrants offered in the concurrent private placement and the shares of common stock underlying such unregistered warrants) were offered and sold by MAIA pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-273984), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on August 15, 2023 and declared effective by the SEC on August 23, 2023. The offering was made only by means of a prospectus supplement that forms a part of this registration statement which was filed with SEC and is available on their website located at http://www.sec.gov . Electronic copies may also be obtained by contacting H.C Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor New York NY 10022 or by phone at (212) 856-5711 or e-mail at placements@hcwco.com .

More on illi News
The offer and sale of unregistered warrants in this private placement were made in a transaction not involving a public offering and have not been registered under Section 4(a)(2) of Securities Act 1933 or Rule 506(b) Regulation D promulgated thereunder nor have they been registered under Securities Act or applicable state securities laws; therefore these unregistered warrants offered in this private placement along with underlying shares may not be reoffered or resold in United States except pursuant to an effective registration statement or an applicable exemption from registration requirements under Securities Act or such applicable state securities laws .

MAIA Biotechnology Inc., is focused on developing first-in-class drugs with novel mechanisms that are intended to improve lives people with cancer; their lead program is THIO which is being developed for treatment NSCLC patients with telomerase positive cancer cells . For more information please visit www .maiabiotech .com
Filed Under: Business
Show All News | Disclaimer | Report Violation

0 Comments

Latest on illi News